首页> 外文OA文献 >Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

【2h】

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

机译：鉴定NVP-BKM120作为一种有效的选择性，口服生物可利用的I类PI3激酶抑制剂，用于治疗癌症

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Matthew T. Burger; Sabina Pecchi; Allan Wagman; Zhi-Jie Ni; Mark Knapp; Thomas Hendrickson; Gordana Atallah; Keith Pfister; Yanchen Zhang; Sarah Bartulis; Kelly Frazier; Simon Ng; Aaron Smith; Joelle Verhagen; Joshua Haznedar; Kay Huh; Ed Iwanowicz; Xiaohua Xin; Daniel Menezes; Hanne Merritt; Isabelle Lee; Marion Wiesmann; Susan Kaufman; Kenneth Crawford; Michael Chin; Dirksen Bussiere; Kevin Shoemaker; Isabel Zaror; Sauveur-Michel Maira; Charles F. Voliva;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class IPI3 kinase for the treatment of cancer [J] . Folkes AJ, Ahmadi K, Alderton WK, Journal of Medicinal Chemistry . 2008,第18期

机译：2-（1H-吲唑-4-基）-6-（4-甲磺酰基-哌嗪-1-基甲基）-4-吗啉-4-基-噻吩并[3,2-d]嘧啶的鉴定（GDC-0941 ）作为有效的，选择性的，口服生物利用的IPI3激酶抑制剂，用于治疗癌症
2. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer [J] . Lewis R.T., Bode C.M., Choquette D.M., Journal of Medicinal Chemistry . 2012,第14期

机译：发现和优化一类新型的，有效的，可口服的，可生物利用的间变性淋巴瘤激酶（ALK）抑制剂，具有潜在的治疗癌症的潜力
3. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors. [J] . Pecchi S, Renhowe PA, Taylor C, Bioorganic and Medicinal Chemistry Letters . 2010,第23期

机译：一类有效的选择性PI3激酶抑制剂2-吗啉代6-（3-羟苯基）嘧啶的鉴定与构效关系。
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. Pharmacological Characterization of TAS05567, a Potent and Selective Inhibitor of Spleen Tyrosine Kinase, in Animal Models of Inflammatory Diseases and B-cell Malignancies [D] . 林宏明 2019

机译：TAS05567，脾酪氨酸激酶的强效和选择性抑制剂，在炎症性疾病和B细胞恶性动物模型中的药理特性
6. Identification of NVP-BKM120 as a Potent Selective Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer [O] . Matthew T. Burger, *, Sabina Pecchi, 2011

机译：NVP-BKM120作为有效的选择性的口服生物利用的I类PI3激酶抑制剂治疗癌症的鉴定
7. Correction to Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase [O] . Sébastien L. Degorce, Bernard Barlaam, Elaine Cadogan, 2018

机译：对新型3-喹啉羧酰胺的发现校正为有效，选择性和口服生物可利用的Ataxia Telanciectasia突变（ATM）激酶的抑制剂

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅